Tonix Pharmaceuticals announces first patient dosed in FOCUS study at MGH

Tonix Pharmaceuticals (TNXP) announced that the first patient has been dosed in the investigator-initiated FOCUS study at Massachusetts General Hospital, MGH, in adult patients with arginine-vasopressin deficiency, AVP-D, a rare endocrine disorder associated with oxytocin deficiency and adverse mental health outcomes, formerly known as central diabetes insipidus. “Patients with AVP-D often experience mental health and quality-of-life challenges that are not adequately addressed by current interventions,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “Oxytocin plays an important role in regulating mood and socioemotional functioning, and evidence suggests that AVP-D is associated with oxytocin deficiency.”